

## REFERENCES

1. Houghton PJ. The role of plants in traditional medicine and current therapy. *J Altern Complem Med* 1995; 1: 131-143.
2. Kudi AC, Umoh JU, Eduvie LO, Gefu J. Screening of some Nigerian medicinal plants for antibacterial activity. *J of Ethnopharm*. 1999; 67: 225-228.
3. Nandy AK, Podder G, Sahu NP, Mahato SB. Triterpenoids and their glucosides from *Terminalia bellerica*. *Phytochem* 1989; 28: 2769-2772.
4. Yadava RN, Rathore K. A new cardenolide from the seeds of *Terminalia bellerica*. *Fitoter*. 2001; 72: 310-312.
5. Muruganandan S, Srinivasan K, Chandra S, Tandan SK, Lal J, RaviprakashKS V. Anti-inflammatory activity of *Syzygium cumini* bark. *Fitoter*. 2001; 72: 369-375.
6. Machado TB, Pinto AV, Pinto MCFR, Leal ICR, Silva MG, Amaral ACF, *et al.* *In vitro* activity of Brazilian medicinal plants, naturally occurring naphthoquinones and their analogues, against methicillin-resistant *Staphylococcus aureus*. *Int J of Antimicro Agents*. 2003; 21: 279-284.
7. Wu TS, Hsu HC, Wu PL, Teng CM, Wu YC. A quinol and steroids from the leaves and stems of *Rhinacanthus nasutus*. *Phytochem*. 1995; 40: 1247-1249.
8. Wu TS, Hsu HC, Wu PL, Leu YL, Chan YY, Chern CY, *et al.* Naphthoquinone Esters from the Root of *Rhinacanthus nasutus*. *Chem & Pharm Bulletin*. 1998; 46: 413-418.
9. Hassell TM. Tissues and cells of the periodontium. *Periodontol 2000*. 1993; 3: 9-38.
10. Bartold PM. Turnover in periodontal connective tissues: dynamic homeostasis of cells, collagen and ground substances. *Oral Dis*. 1995; 1: 238-253.
11. Hefti AF. Aspects of cell biology of the normal periodontium. *Periodontol 2000*. 1993; 3: 64-75.
12. Pitaru S, McCulloch C, Narayanan AS. Cellular origins and differentiation control mechanisms during periodontal development and wound healing. *J Periodont Res*. 1994; 29: 81-94.
13. Bartold PM, Narayanan AS, editors. Biology of the periodontal connective tissues. 1<sup>st</sup> ed. Illinois: Quintessence; 1998.

14. Page R. The role of inflammatory mediators in the pathogenesis of periodontal disease. *J Periodont Res.* 1991; 26: 230-242.
15. Loesche WJ. Bacterial mediators in periodontal disease. *Clin Infect Dis.* 1993;16:203-210.
16. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. *Periodontol 2000.* 1994; 5: 78-111.
17. The American Academy of Periodontology. The pathogenesis of periodontal diseases. *J Periodontol.* 1999; 70: 457-470.
18. Kinane DF. Causation and pathogenesis of periodontal disease. *Periodontol 2000.* 2001; 25: 8-20.
19. Meyer DH, Miniz KP, Five-Taylor PM. Models of invasion of enteric and periodontal pathogens into epithelial cells : a comparative analysis. *Crit Rev Oral Biol Med.* 1997; 8: 389-409.
20. Dorn BR, Leung KP, Fox AP. Invasion of human oral epithelial cells by *Prevotella intermedia*. *Infect and immun.* 1998; 66: 6054-6057.
21. Offenbacher S. Periodontal diseases: Pathogenesis. *Ann Periodontol.* 1996; 1: 821-878.
22. Rietschel ET, Brade H. Bacterial endotoxins. *Sci Am.* 1992; 267: 54-61.
23. Graves DT. The potential role of chemokines and inflammatory cytokines in periodontal disease progression. *Clin Infect Dis.* 1999; 28: 482-552.
24. Haake SK, Nisengard RJ, Newman MG, Miyasaki KT. Microbial interactions with the host in periodontal diseases. In: Newman MG, Takei HH, Carranza FA, eds. Carranza's clinical periodontology. Philadelphia: Saunders; 2002: 132-152.
25. Kornman KS. Host modulation as a therapeutic strategy in the treatment of periodontal disease. *Clin Infect Dis.* 1999; 28: 520-532.
26. Offenbacher S, Salvi GE. Induction of prostaglandin release from macrophages by bacterial endotoxin. *Clin Infect Dis.* 1999; 28: 505-520.
27. Nisengard RJ, Newman MG, Zambon JJ. Periodontal disease. In: Nisengard RJ, Newman MG, eds. Oral Microbiology and immunology. 2<sup>nd</sup> ed. Philadelphia:WB Saunders, 1994: 385-390.
28. Armitage GC. Development of classification system for periodontal diseases and conditions. *Ann Periodontol.* 1999; 1-6.

29. Moore WE, Moore LV. The bacteria of periodontal diseases. *Periodontol 2000*. 1994; 5: 66-92.
30. Tonetti MS, Mombelli A. Early-onset periodontitis. *Ann Periodontol*. 1999; 4: 39-53.
31. Liebana J, Castillo AM, Alvalez M. Periodontal diseases: microbiological considerations. *Med Oral Patol Oral Cir Bucal*. 2004; 9: 75-91.
32. Marsh P, Martin MV, editors. Periodontal disease. Oral Microbiology. 4th ed. Oxford:Wright; 1999; 104-26.
33. Marsh P, Martin MV, editors. The resident oral microflora. Oral Microbiology. 4th ed. Oxford:Wright; 1999; 17-33.
34. Fives-Taylor PM, Meyer DH, Mintz KP, Brissette C. Virulence factors of *Actinobacillus actinomycetemcomitans*. *Periodontol 2000*. 1999; 20: 136-167.
35. Henderson B, MW, Sharp L, Ward JM. *Actinonacillus actinomycetemcomitans*. *J of Med Microbio*. 2002; 51: 1013-1020.
36. Holt SC, Kesavalu L, Walker S, Genco CA. Virulence factors of *Porphyromonas gingivalis*. *Periodontol 2000*. 1999; 20: 168-238.
37. Darveau RP, Belton CM, Reife RA, Lamont RJ. Local chemokine paralysis, a novel pathogenic mechanism for *Porphyromonas gingivalis*. *Infect and immun*. 1998; 66: 1660-1665.
38. Wilson TG, Kornman KS, editors. Microbiology and etiology of periodontal diseases. Fundamentals of periodontics. 2nd ed. Chicago: Quintessence; 2003; 46-66.
39. Slots J. Selection of antimicrobial agents in periodontal therapy. *J Periodont Res*. 2002; 37: 389-398.
40. Ting M, Slot J. Systemic antibiotics in the treatment of periodontal disease. *Periodontol 2000*. 2002; 28: 106-176.
41. Goodson JM. Antimicrobial strategies for treatment of periodontal diseases. *Periodontol 2000*. 1994; 5: 142-168.
42. Quirynen M, Teughels W, van Steenberghe D. Microbial shifts after subgingival debridement and formation of bacterial resistance when combine with local or systemic antimicrobials. *Oral Dis*. 2003; 9: 30-37.
43. Cobb CM. Non-surgical pocket therapy: Mechanical. *Ann Periodontol*. 1996; 1: 443-490.

44. Garrett S, Johnson L, Drisko CH, Adams DF, Bandt C, Beiswanger B, *et al.* Two multi-center studies evaluating locally delivered doxycycline hyclate, placebo control, oral hygiene, and scaling and root planing in the treatment of periodontitis. *J Periodontol.* 1999; 70: 490-503.
45. Addy M, Martin MV. Systemic antimicrobials in the treatment of chronic periodontal diseases: a dilemma. *Oral Dis.* 2003; 9(1): 38-44.
46. Etienne D. Locally delivered antimicrobials for the treatment of chronic periodontitis. *Oral Dis.* 2003; 9(1): 45-50.
47. Williams RC, Paquette DW, Offenbacher S, Adams DF, Armitage GC, Bray K, *et al.* Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. *J Periodontol.* 2001; 72: 1535-1544.
48. Trombelli L, Tatakis DN. Periodontal diseases: current and future indications for local antimicrobial therapy. *Oral Dis.* 2003; 9: 11-15.
49. Mombelli A. Periodontitis as an infectious disease : specific features and their implications. *Oral dis.* 2003; 9: 6-10.
50. The role of controlled drug delivery for periodontitis (editorial). *J Periodontol.* 2000; 71: 125-140.
51. Ryan ME. Clinical applications for host modulatory therapy. *Conpend.* 2002; 23: 1071-1082.
52. Preshaw PM, Hefti AF, Novak MJ, Michalowicz BS, Pihlstrom BL, Schoor R, *et al.* Subantimicrobial dose doxycycline enhances the efficacy of scaling and root planing in chronic periodontitis: a multicenter trial. *J Periodontol.* 2004; 75: 1068-1076.
53. Mombelli A, Schmid B, Rutarand A, Lang NP. Local antibiotic therapy guided by microbiological diagnosis: Treatment of *Porphyromonas gingivalis* and *Actinobacillus actinomycetemcomitans* persisting after mechanical therapy. *J Clin Periodontol.* 2002; 29: 743-749.
54. Rassameemaasmaung S, Sirirat M, Komwatchara T, Rajanapanthu P, Yudhasaraprasithi S, Amornchat C, *et al.* Subgingival administration of *Andrographis Paniculata* gel as an adjunct in the treatment of adult periodontitis. *Mahidol J.* 1998; 5: 9-15.
55. Akinpelu DA. Antimicrobial activity of *Anacardium occidentale* bark. *Fitoter.* 2001; 72: 286-287.

56. Ibewuike J, Ogundaini AO, Bohlin L, Ogungbamila FO. Anti-inflammatory activity of selected Nigerian medicinal plants. *Nig J Nat Prod And Med.* 1997; 1: 10-14.
57. Olajide OA, Aderogba M, Adedapo AD, Makinde JM. Effects of *Anacardium occidentale* stem bark extract on in vivo inflammatory models. *J Ethnopharm.* 2004; 95(2-3): 139-142.
58. Holetz FB, Pessini GL, Sanches NR, Cortez DAG, Nagamura CV, *et al.* Screening of some plants used in the brazilian folk for the treatment of infectious diseases. *Memo do Instio Oswal Cruz.* 2002; 97(7): 1027-1031.
59. Lansky EP, Newman RA. Review *Punica granatum* (pomegranate) and its potential for prevention and treatment of inflammation and cancer. *J of Ethnopharm.* 2007; 109: 177-206.
60. Fransworth NR, Bunyapraphatsara N, (editorial). Thai medicinal plants: plant recommended for primary health care system. Bangkok: Prachachon. 1992.
61. Koneman EW, Janda WM, Allen SD, Sommers HM, Dowell VR, Winn WC,Jr. Antimicrobial susceptibility testing. Color atlas and textbook of diagnostic microbiology. 3rd ed. Philadelphia: J.B. Lippincott; 1988; 473-533.
62. Kasugai S, Hasegawa N, Ogura H. A simple in vitro cytotoxicity test using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric assay: analysis of eugenol toxicity on dental pulp cells (RPC-C2A). *Jpn J Pharmacol.* 1990; 52: 95-100.
63. Takiguchi H, Yamaguchi M, Mochizuki K, Abiko Y. Effect of in vitro aging on *Campylobacter rectus* lipopolysaccharide-stimulated PGE2 release from human gingival fibroblasts. *Oral Dis.* 1996; 2: 202-209.
64. Corbet EF, Zee KY, Lo ECM. Periodontal diseases in Asia and Oceania. *Periodontol 2000.* 2002; 29: 122-152.
65. Brown LJ, Brunelle JA, Kingman A. Periodontal status in the United States, 1988-1991: prevalence, extent, and demographic variation. *J Dent Res.* 1996; 75: 672-683.
66. Baelum V, Pisuttanakan S, Teanpaisan R, Pithponchaiyakul W, Pongpaisal S, Papapanou PN, *et al.* Periodontal conditions among adults in Southern Thailand. *J Periodont Res.* 2003; 38: 156-163.

67. Offenbacher S, Beck JD. Relationships among clinical measures of periodontal disease and their associations with systemic markets. *Ann Periodont.* 2002; 7: 79-89.
68. Mealey BL. Influence of periodontal infections on systemic health. *Periodontol 2000.* 1999; 21: 197-209.
69. Riche EL, Boggess KA, Lieff S, Murtha AP, Auten RL, Beck JD, et al. Periodontal disease increases the risk of preterm delivery among preeclamptic women. *Ann Periodontol.* 2002; 7: 95-101.
70. Xing L, Remick DG. Mechanisms of dimethyl sulfoxide augmentation IL-1 $\beta$  production. *J of Immuno.* 2005; 174: 6195-6202.
71. Ahmad I, Mehmood Z, Mohammad F. Screening of some Indian medical plants for their antimicrobial properties. *J of Ethnopharm.* 1998; 62: 183-193.
72. Shafi PM, Rosamma MK, Jamil K, Reddy PS. Antibacterial activity of *Syzygium cumini* and *Syzygium travancoricum* leaf essential oils. *Fitoter.* 2002; 73: 414-416.
73. Meledez PA, Capriles VA. Antibacterial properties of tropical plants from Puerto Rico. *Phytomed.* 2006; 13: 272-276.
74. Prashanth D, Asha MK, Amit A. Antibacterial activity of *Punica granatum*. *Fitoter.* 2001; 72: 171-173.
75. Voravuthikunchai S, Lortheeranuwat A, Jeeju W, Sririrak T, Phongpaichit S, Supawita T. Effective medicinal plants against enterohaemorrhagic *Escherichia coli* 0157:H7. *J of Ethnopharm.* 2004; 94: 49-54.
76. Atsawasuan P, Sirirat M, Amornchat C, Yudhasaraprasithi S, Rassameemaasmaung S, Rajanapanthu P, et al. Subgingival administration of *Andrographis Paniculata* gel and metronidazole gel as an adjunct in the treatment of adult periodontitis : clinical and microbiological effects. *Mahidol J.* 1998; 5: 97-101.
77. Konan NA, Bacchi EM, Lincopan N, Varela SD, Varanda EA. Acute, subacute toxicity and genotoxic effect of hydroethanolic extract of the cashew (*Anacardium occidentale* L.). *J of Ethnopharm.* 2007; 110: 30-38.
78. Mosmann T. Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays. *J of Immuno Met.* 1983; 65: 55-63.

79. Gerlier D, Thomasset N. Use of MTT colorimetric assay to measure cell activation. *J of Immuno Met.* 1986; 94; 57-63.
80. Thunyakitpisal P, Damrongsri D, Charearnwetchatom N, Boonyaratanaasontorn S, Udomkittanasarn S. Effect of Aloe vera gel and exudate extracts on the proliferation of primary cultured gingival fibroblasts and keratinocyte, *in vitro*. *CU Dent J.* 2002; 25: 61-70.
81. Choi SW, Son BW, Son YS, Park YI, Lee SK, Chung MH. The wound healing effect of a glycoprotein fraction isolated from aloe vera. *Br J Dermatol.* 2001; 145: 535-545.
82. Howling GI, Dettmar PW, Goddard PA, Hampson FC, Dornish M, Wood EJ. The effect of chitin and chitosan on the proliferation of human skin fibroblasts and keratinocytes *in vitro*. *Biomat.* 2001; 22: 2959-2966.
83. Havesteen BH. The biochemistry and medicinal significance of the flavonoids. *Pharmacol and Therapeut.* 2002; 96: 67-202.
84. Fernandes E, Carvalho M, Carvalho F, Silva AM, Pinto DC, Cavaleiro JA. Hepatoprotective activity of polyhydroxylated 2-styrylchromosomes against *tert*-butylhydroperoxide induced toxicity in freshly isolated rat hepatocytes. *Arc of Toxic.* 2003; 500-505.
85. Satyanarayana PS, Singh D, Chopra K. Quercetin, a bioflavonoid, protects against oxidative stress-related renal dysfunction by cyclosporine in rats. *Met and find in experimen and clin pharm.* 2001; 34: 175-181.
86. Yokozawa T, Fujioka K, Oura H, Nonaka G, Nishioka I. Effects of rhubarb tannins on urinemic toxins. *Nephron.* 1991; 58: 155-160.
87. Squillaci G, Maggio GD. Acute morbidity and mortality from decoctions of bark of *Punica granatum*. *Bullet Soci Italia Bio Speriment.* 1946; 1095-1096.
88. Vidal A, Fallarero A, Pena BR, Medina ME, Gra B, Rivera F. Studies on the toxicity of *Punica granatum* L. (Punicaceae) whole fruit extracts. *J of Ethnopharm.* 2003; 89: 295-300.
89. Fatope MO, Burtonmani SK, Takeda Y. Monoacylglycerol from *Punica granatum* seed oil. *J of Agricul and food chem.* 2002; 50: 357-360.